Bouhassira Didier, Attal Nadine, Fermanian Jacques, Alchaar Haiel, Gautron Michèle, Masquelier Etienne, Rostaing Sylvie, Lanteri-Minet Michel, Collin Elisabeth, Grisart Jacques, Boureau François
INSERM E-332, Centre d'Evaluation et de Traitement de la Douleur, Hôpital Ambroise Paré, Boulogne-Billancourt, France Université Versailles Saint-Quentin, Versailles, France Service de Biostatistique, Hôpital Necker, Paris, France Hôpital Pasteur, Nice, France Cliniques Universitaires Saint-Luc, Brussels, Belgium Hôpital Saint-Antoine, Paris, France Hôpital Pitié-Salpêtrière, Paris, France.
Pain. 2004 Apr;108(3):248-257. doi: 10.1016/j.pain.2003.12.024.
This study describes the development and validation of the Neuropathic Pain Symptom Inventory (NPSI), a new self-questionnaire specifically designed to evaluate the different symptoms of neuropathic pain. Following a development phase and a pilot study, we generated a list of descriptors reflecting spontaneous ongoing or paroxysmal pain, evoked pain (i.e. mechanical and thermal allodynia/hyperalgesia) and dysesthesia/paresthesia. Each of these items was quantified on a (0-10) numerical scale. The validation procedure was performed in 176 consecutive patients with neuropathic pain of peripheral (n = 120) or central (n = 56) origin, recruited in five pain centers in France and Belgium. It included: (i) assessment of the test-retest reliability of each item, (ii) determination of the factorial structure of the questionnaire and analysis of convergent and divergent validities (i.e. construct validity), and (iii) evaluation of the ability of the NPSI to detect the effects of treatment (i.e. sensitivity to change). The final version of the NPSI includes 10 descriptors (plus two temporal items) that allow discrimination and quantification of five distinct clinically relevant dimensions of neuropathic pain syndromes and that are sensitive to treatment. The psychometric properties of the NPSI suggest that it might be used to characterize subgroups of neuropathic pain patients and verify whether they respond differentially to various pharmacological agents or other therapeutic interventions.
本研究描述了神经病理性疼痛症状量表(NPSI)的开发与验证过程,这是一种专门设计用于评估神经病理性疼痛不同症状的新型自我调查问卷。经过一个开发阶段和一项初步研究,我们生成了一份描述符列表,反映自发持续性或阵发性疼痛、诱发性疼痛(即机械性和热性感觉异常/痛觉过敏)以及感觉异常/感觉异常。这些项目中的每一项都在(0 - 10)数字量表上进行量化。验证程序在法国和比利时的五个疼痛中心招募的176例连续的外周性(n = 120)或中枢性(n = 56)神经病理性疼痛患者中进行。它包括:(i)评估每个项目的重测信度,(ii)确定问卷的因子结构并分析收敛效度和区分效度(即结构效度),以及(iii)评估NPSI检测治疗效果的能力(即对变化的敏感性)。NPSI的最终版本包括10个描述符(加上两个时间项目),这些描述符能够区分和量化神经病理性疼痛综合征的五个不同的临床相关维度,并且对治疗敏感。NPSI的心理测量特性表明,它可用于对神经病理性疼痛患者亚组进行特征描述,并验证他们对各种药物或其他治疗干预的反应是否存在差异。